©2020-2032 All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.
Online Journal of Bioinformatics©
Volume 21(2): 168-181, 2020.
In silico multi-epitope severe fever thrombocytopenia syndrome vaccine targets virus membrane glycoprotein.
Ramya Bandarupalli1, Bhavana Kasaraneni1, Chandana Madala1, Lahari Paladugu1, Kanaka Durga Devi Nelluri2*
1Department(s) of Pharmacy Practice, 2Pharmaceutics and Biotechnology, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, India. *Corresponding Author: Dr.Nelluri Kanaka Durga Devi,
Bandarupalli R, Kasaraneni B, Madala C, Paladugu L, Devi Nelluri KD., In silico multi-epitope severe fever thrombocytopenia syndrome vaccine targets virus membrane glycoprotein, Onl J Bioinform., 21(2): 168-181, 2020. Thrombocytopenia syndrome virus (SFTSV) can cause ~10-30% mortality in humans currently with no vaccine or drugs for treatment. We describe an In silico multi-epitope vaccine targeting SFTSV membrane glycoprotein polyprotein to predict B and T-cell epitopes for immunogenicity, allergenicity, toxicity and conservancy. Epitopes were screened by docking with HLA alleles to generate highest immune response. The 3D model vaccine was docked with Toll-like receptor-8 by molecular dynamic simulations. Further codon adaptation of vaccine sequence was cloned in silico in plasmid pIB2 vector to ensure expression efficiency at production. Results need to be supported in vitro and in vivo for efficacy and safety.
KEYWORDS: SFTSV; Multi-epitope vaccine; membrane glycoprotein polyprotein; Immuno-informatics; Vaccine design.